Z. Dayao

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Z. Dayao, Z. R. Dayao, Z Dayao, Zoneddy R. Dayao, Zoneddy Ruiz Dayao, Zoneddy Dayao
Publication record
62 papers · 788 citations · H-index 12

PAPERS

Abstract RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
20260 citationsauthor #14
Implementation factors for sexual orientation and gender identity patient data collection in a comprehensive cancer center: findings from a center-wide readiness assessment survey for the ASK Sexual Orientation and Gender Identity study.
20250 citationsauthor #8
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
20251 citationsauthor #15
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
20250 citationsauthor #29
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
202428 citationsauthor #7
Developing questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
20240 citationsauthor #8
Abstract PO3-02-05: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
20240 citationsauthor #14
Abstract IA016: Best practice strategies for SOGI data collection: Lessons learned from conducting and implementing the Ask SOGI study
20230 citationsauthor #9
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2
202310 citationsauthor #2
Abstract B069: Patient perspectives on reimagining survivorship care: A “Chipotle” model to enhance personalized cancer recovery
20230 citationsauthor #6
Developing Questions to Assess and Measure Patients’ Perceived Survival Benefit from Adjuvant Endocrine Therapy in Breast Cancer: A Mixed Methods Pilot Study
20230 citationsauthor #7
Impact of audio-visual tool on patient comfort level at a comprehensive cancer center infusion suite: Preliminary results.
20230 citationsauthor #7
“Care needs to be integrated” Patient and provider perspectives on a cancer shared-care model
20234 citationsauthor #7
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A.
20222 citationsauthor #3
Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study
202231 citationsauthor #10
Patient-Reported Measures of a Breast Cancer Nurse Navigator Program in an Underserved, Rural, and Economically Disadvantaged Patient Population.
20222 citationsauthor #3
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)
20220 citationsauthor #7
Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)
20221 citationsauthor #29
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
202286 citationsauthor #3
Improving Outpatient Infusion Clinic Wait Times at a Comprehensive Cancer Center
20213 citationsauthor #8
Developing a survivorship care plan (SCP) delivery process for patients and primary care providers serving poor, rural, and minority patients with cancer
20219 citationsauthor #14
Patient, provider, and nurse preferences regarding patient-reported outcomes (PRO) and side effect management during cancer treatment of minority, rural and economically disadvantaged patients.
20210 citationsauthor #9
Characterizing Low-Risk Breast and Gynecological Cancer Patients for Transition into an Oncology/Primary Care Coordinated Care Model: Findings from a Survey of Diverse Survivors in a Rural U.S. State
20213 citationsauthor #8
Southwest Harvest for Health: An Adapted Mentored Vegetable Gardening Intervention for Cancer Survivors
202113 citationsauthor #14
Southwest Harvest for Health: Adapting a mentored vegetable gardening intervention for cancer survivors in the southwest
20216 citationsauthor #11
Abstract B015: Women in survivorship health using Project ECHO: Creating a model for navigated care transitions
20200 citationsauthor #3
Pharmacist-Driven Oral Oncolytic Medication Education and Consent.
20201 citationsauthor #6
Streamlining survivorship care plan (SCP) creation and delivery to primary care providers in poor, rural, and minority patients.
20201 citationsauthor #11
Optimizing infusion wait time: Redesigning medication order verification/approval at a comprehensive cancer center.
20200 citationsauthor #2
Oral oncolytic education and adherence monitoring in poor, rural and minority patients.
20200 citationsauthor #6
Developing a Survivorship Care Transition Model for Rural and Underserved Low Risk Breast and Gynecologic Cancer Patients
20200 citationsauthor #7
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
202058 citationsauthor #12
Abstract P6-11-10: Patient reported measures of a breast cancer nurse navigator program in a minority, rural, and economically disadvantaged patient population
20201 citationsauthor #3
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
202083 citationsauthor #5
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome.
20200 citationsauthor #1
Stop testing the patience of our patients – Optimizing workflow at a Cancer Center Infusion Suite
20200 citationsauthor #2
Building a survivorship care plan delivery process: Experience in an academic center.
20190 citationsauthor #1
Pharmacist-driven oral oncolytic medication education and consent.
20194 citationsauthor #3
Abstract P5-13-06: Analysis of barriers to clinical trial accrual in an NCI-designated comprehensive cancer center: Results of identifying clinical trial gaps
20191 citationsauthor #1
Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.
20197 citationsauthor #12
Virtual Breast Cancer Clinic: An Innovative Interactive Educational Curriculum
20190 citationsauthor #3
Experiences with multiplex testing for inherited breast cancer at an academic comprehensive cancer center
20180 citationsauthor #1
The Conundrum of Adjuvant HER2 Treatment Options
20184 citationsauthor #3
Improving start-up times in oncology clinical trials: An ASCO quality improvement project.
20181 citationsauthor #3
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
2017288 citationsauthor #26
Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families
20170 citationsauthor #6
Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families
201711 citationsauthor #6
Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families
201717 citationsauthor #8
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52
201741 citationsauthor #7
Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature
20169 citationsauthor #5
HER2-targeted therapy for early-stage breast cancer: a comprehensive review.
201427 citationsauthor #2
Abstract 1710: Quantitative 3D mapping of total choline in human breast cancer using high-speed MR spectroscopic imaging at 3T
20120 citationsauthor #4
Abstract P3-03-01: 3D mapping of total choline in human breast cancer using high-speed MR spectroscopic imaging at 3T: initial experience during neoadjuvant therapy
20120 citationsauthor #4
The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer
20127 citationsauthor #2
Association of CYP19A1 gene variants with differences in disease progression in breast cancer patients from different racial/ethnic backgrounds.
20120 citationsauthor #7
Abstract PD07-01: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on 2 to 4 week Ki67 level > 10%.
201216 citationsauthor #14
3 D Mapping of total Choline in Human Breast Cancer Using High-Speed MR Spectroscopic Imaging at 3 T : Initial Experience during Neoadjuvant Therapy
20110 citationsauthor #4
P2-10-04: 3D Mapping of Total Choline in Human Breast Cancer Using High-Speed MR Spectroscopic Imaging at 3T: A Feasibility Study.
20110 citationsauthor #3
Distant Metastases: A Surrogate Endpoint for Overall Survival in Early Breast Cancer?
20110 citationsauthor #2
Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case-Control Study in Denmark: Bosco JLF, Antonsen S, Sørensen HT, et al (Boston Univ School of Medicine, MA; Aarhus Univ Hosp, Denmark) Cancer Epidemiol Biomarkers Prev 20:101-111, 2011§
201114 citationsauthor #2
Prevalence of BRCA1/2 Mutations and Variants in a Southwest Hispanic Population.
20090 citationsauthor #3
135Anti-CD3 stimulated T regulatory cells do not inhibit syngeneic bone marrow progenitor cell proliferation
20030 citationsauthor #1

TIMELINE

2003 0 citations

2009 0 citations

2011 14 citations

2012 23 citations

2014 27 citations

2016 9 citations

2017 357 citations

2018 5 citations

2019 12 citations

2020 144 citations

2021 34 citations

2022 122 citations

2023 14 citations

2024 28 citations

2025 1 citations

2026 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT